Baseline characteristics predicting clinical outcomes and serious adverse events in middle-aged hypertensive women: a subanalysis of the SPRINT in women aged <65 years

Objective & Hypothesis:Background/aim: The predictability of clinical outcomes in hypertension in specific patient groups, especially underrepresented populations is the key to rational treatment.

📊

Key Findings & Data:Background/aim: The predictability of clinical outcomes in hypertension in specific patient groups, especially underrepresented populations is the key to rational treatment.

💡

Conclusion & Impact:This study aimed to investigate the impact of baseline characteristics of

🔬Design:Research Article

📍Scope:Comprehensive Sample

⚙️Variables:Domain Parameters

Abstract

Background/aim: The predictability of clinical outcomes in hypertension in specific patient groups, especially underrepresented populations is the key to rational treatment. This study aimed to investigate the impact of baseline characteristics of

🔖

Cite This Article

SAKARYA, S., AKMAN, M., AKICI, A., AYDIN, V., FAK, A. S. (2022). Baseline characteristics predicting clinical outcomes and serious adverse events in middle-aged hypertensive women: a subanalysis of the SPRINT in women aged <65 years. Turkish Journal of Medical Sciences, Cilt: 50 - Sayı: 5, 1298–1306. https://ajindex.com/articles/609859

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (13)

Humphries KH, Izadnegahdar M, Sedlak T, Saw J, Johnston N et al. Sex differences in cardiovascular disease – impact on care and outcomes. Frontiers in Neuroendocrinology 2017; 46: 46-70
Joyner MJ, Barnes JN, Hart EC, Wallin BG, Charkoudian N. Neural control of the circulation: how sex and age differences interact in humans. Comprehensive Physiology 2015; 5 (1): 193- 215
Abramson BL, Melvin RG. Cardiovascular risk in women: focus on hypertension. Canadian Journal of Cardiology 2014; 30 (5): 553-559
Appelman Y, Van Rijn BB, Ten Haaf ME, Boersma E, Peters SA. Sex differences in cardiovascular risk factors and disease prevention. Atherosclerosis 2015; 241 (1): 211-218
Wenger NK, Ferdinand KC, Bairey Merz CN, Walsh MN, Gulati M et al. Women, hypertension, and the systolic blood pressure intervention trial. The American Journal of Medicine 2016; 129 (10): 1030-1036
Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR et al. Heart disease and stroke statistics - 2018 update: a report from the American Heart Association. Circulation 2018; 137 (12): e67-e492
Turnbull F, Woodward M, Neal B, Barzi F, Ninomiya T et al. Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. European Heart Journal 2008; 29 (21): 2669- 2680
Merz AA, Cheng S. Sex differences in cardiovascular ageing. Heart 2016; 102 (11): 825-831
Wenger NK, Arnold A, Bairey Merz CN, Cooper-DeHoff RM, Ferdinand KC et al. Hypertension across a woman’s life cycle. Journal of the American College of Cardiology 2018; 71 (16): 1797-1813
Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/ NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Journal of the American College of Cardiology 2018; 71 (19): e127-248
Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal 2018; 39 (33): 3021-3104
Melloni C, Berger JS, Wang TY, Gunes F, Stebbins A et al. Representation of women in randomized clinical trials of cardiovascular disease prevention. Circulation Cardiovascular Quality and Outcomes 2010; 3 (2): 135-142
Scott PE, Unger EF, Jenkins MR, Southworth MR, McDowell TY et al. Participation of women in clinical trials supporting FDA approval of cardiovascular